Why Are Journey Medical Shares Trading Lower Today?
Portfolio Pulse from Vandana Singh
Journey Medical Corporation's shares are trading lower after the company announced topline results from two Phase 3 trials of DFD-29 for adult patients with moderate-to-severe papulopustular rosacea. The trials achieved the co-primary and all secondary endpoints with no significant safety issues. DFD-29 is being developed in collaboration with Dr. Reddy's Laboratories Ltd.
July 11, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Journey Medical's stock price is trading lower after the announcement of successful Phase 3 trials of DFD-29.
Despite the successful trials, the market may have expected more from the results, leading to a drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Dr. Reddy's Laboratories is collaborating with Journey Medical on the development of DFD-29.
As a collaborator on the DFD-29 development, the news could have an impact on Dr. Reddy's Laboratories, but the extent of the impact is unclear.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50